RRM2 induces NF-κB-dependent MMP-9 activation and enhances cellular invasiveness

Biochemical and Biophysical Research Communications

Volumn 354, Issue 1, 2007, Pages 190-196

  Duxbury, Mark S ^a   Whang, Edward E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Invasion; Invasiveness; MAPK; Metalloproteinase; MMP 9; NF B; Pancreas; Pancreatic adenocarcinoma; Pancreatic cancer; Ribonucleotide reductase; RRM2

Indexed keywords

2' DEOXYRIBONUCLEOSIDE 5' TRIPHOSPHATE; DEOXYRIBONUCLEOSIDE; DEOXYRIBONUCLEOTIDE; ENZYME; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATE; PROTEIN RRM2; PROTEIN SUBUNIT; RIBONUCLEOTIDE; RIBONUCLEOTIDE 2' DEOXYNUCLEOTIDE; RIBONUCLEOTIDE 5' DIPHOSPHATE; RIBONUCLEOTIDE REDUCTASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CATALYSIS; CELL ACTIVITY; CELL FUNCTION; CELL INVASION; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVATION; ENZYME STRUCTURE; FUNCTIONAL PROTEOMICS; GENE EXPRESSION REGULATION; GENE INDUCTION; GENE OVEREXPRESSION; GENE SILENCING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; RNA INTERFERENCE;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; PANCREATIC NEOPLASMS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE;

EID: 33846296549     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.12.177     Document Type: Article

References (39)

1. Cory J.G., and Sato A. Regulation of ribonucleotide reductase activity in mammalian cells. Mol. Cell. Biochem. 53-54 (1983) 257-266
2. Cory J.G. Purine and pyrimidine nucleotide metabolism. In: Devlin T. (Ed). Biochemistry with Clinical Correlations (1997), Wiley-Liss, New York
3. Goan Y.G., Zhou B., Hu E., Mi S., and Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res. 59 (1999) 4204-4207
4. Reichard P. From deoxynucleotides to DNA synthesis. Fed. Proc. 37 (1978) 9-14
5. Reichard P. Ribonucleotide reductase and deoxyribonucleotide pools. Basic Life Sci. 31 (1985) 33-45
6. Shao J., Zhou B., Zhu L., Qiu W., Yuan Y.C., Xi B., and Yen Y. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64 (2004) 1-6
7. Guittet O., Hakansson P., Voevodskaya N., Fridd S., Graslund A., Arakawa H., Nakamura Y., and Thelander L. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J. Biol. Chem. 276 (2001) 40647-40651
8. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., and Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
9. Eriksson S., and Martin Jr. D.W. Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J. Biol. Chem. 256 (1981) 9436-9440
10. Bjorklund S., Skog S., Tribukait B., and Thelander L. S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry 29 (1990) 5452-5458
11. Thelander M., Graslund A., and Thelander L. Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells. J. Biol. Chem. 260 (1985) 2737-2741
12. Zhou B.S., Tsai P., Ker R., Tsai J., Ho R., Yu J., Shih J., and Yen Y. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin. Exp. Metastasis 16 (1998) 43-49
13. Raitano A.B., Scuderi P., and Korc M. Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas 5 (1990) 267-277
14. Jong A.Y., Yu K., Zhou B., Frgala T., Reynolds C.P., and Yen Y. A simple and sensitive ribonucleotide reductase assay. J. Biomed. Sci. 5 (1998) 62-68
15. Shen Z., Peedikayil J., Olson G.K., Siebert P.D., and Fang Y. Multiple transcription factor profiling by enzyme-linked immunoassay. Biotechniques 32 (2002) 1168 1170-2, 1174
16. Kunsch C., Ruben S.M., and Rosen C.A. Selection of optimal kappa B/Rel DNA-binding motifs: interaction of both subunits of NF-kappa B with DNA is required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 4412-4421
17. Pessara U., and Koch N. Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element. Mol. Cell. Biol. 10 (1990) 4146-4154
18. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., and Whang E.E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23 (2003) 1539-1548
19. Duxbury M.S., Ito H., Benoit E., Zinner M.J., Ashley S.W., and Whang E.E. Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer. Surgery 136 (2004) 261-269
20. Algul H., Adler G., and Schmid R.M. NF-kappaB/Rel transcriptional pathway: implications in pancreatic cancer. Int. J. Gastrointest. Cancer 31 (2002) 71-78
21. Arlt A., Gehrz A., Muerkoster S., Vorndamm J., Kruse M.L., Folsch U.R., and Schafer H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22 (2003) 3243-3251
22. Muerkoster S., Arlt A., Witt M., Gehrz A., Haye S., March C., Grohmann F., Wegehenkel K., Kalthoff H., Folsch U.R., and Schafer H. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int. J. Cancer 104 (2003) 469-476
23. Sclabas G.M., Fujioka S., Schmidt C., Evans D.B., and Chiao P.J. NF-kappaB in pancreatic cancer. Int. J. Gastrointest. Cancer 33 (2003) 15-26
24. Zhou B., Mo X., Liu X., Qiu W., and Yen Y. Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance. Cytogenet. Cell Genet. 95 (2001) 34-42
25. Ito H., Gardner-Thorpe J., Zinner M.J., Ashley S.W., and Whang E.E. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 134 (2003) 221-226
26. Ali M.A., McWeeney D., Milosavljevic A., Jurka J., and Jariwalla R.J. Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2. Proc. Natl. Acad. Sci. USA 88 (1991) 8257-8261
27. Mann G.J., Musgrove E.A., Fox R.M., and Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence, and differentiation. Cancer Res. 48 (1988) 5151-5156
28. Zhou B.S., Hsu N.Y., Pan B.C., Doroshow J.H., and Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res. 55 (1995) 1328-1333
29. Schallreuter K.U., Elgren T.E., Nelson Jr. L.S., MacFarlan S., Yan-Sze I., and Hogenkamp H.P. Ribonucleotide diphosphate reductase from human metastatic melanoma. Melanoma Res. 2 (1992) 393-400
30. Farina A.R., Tacconelli A., Vacca A., Maroder M., Gulino A., and MacKay A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differ. 10 (1999) 353-367
31. Ricca A., Biroccio A., Del Bufalo D., MacKay A.R., Santoni A., and Cippitelli M. bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7(ADR) breast-cancer cells. Int. J. Cancer 86 (2000) 188-196
32. Yan C., Wang H., and Boyd D.D. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J. Biol. Chem. 276 (2001) 1164-1172
33. Harimaya K., Tanaka K., Matsumoto Y., Sato H., Matsuda S., and Iwamoto Y. Antioxidants inhibit TNFalpha-induced motility and invasion of human osteosarcoma cells: possible involvement of NFkappaB activation. Clin. Exp. Metastasis 18 (2000) 121-129
34. Huang S., Pettaway C.A., Uehara H., Bucana C.D., and Fidler I.J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20 (2001) 4188-4197
35. Sato H., and Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8 (1993) 395-405
36. He C. Molecular mechanism of transcriptional activation of human gelatinase B by proximal promoter. Cancer Lett. 106 (1996) 185-191
37. Wang Z., Sengupta R., Banerjee S., Li Y., Zhang Y., Rahman K.M., Aboukameel A., Mohammad R., Majumdar A.P., Abbruzzese J.L., and Sarkar F.H. Epidermal growth factor receptor-related protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res. 66 (2006) 7653-7660
38. Fan H., Villegas C., Huang A., and Wright J.A. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 58 (1998) 1650-1653
39. Khosravi-Far R., and Der C.J. The Ras signal transduction pathway. Cancer Metastasis Rev. 13 (1994) 67-89